Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16702937 | 0.96 | NAAA (0.50) | NAAACYP1A2SIGMAR1EPHX1EPHX2 | |
| SCHEMBL6024059 | 0.92 | NAAA (0.46) | NAAACYP1A2SIGMAR1EPHX1EPHX2 | |
| SCHEMBL23501850 | 0.87 | NAAA (0.38) | NAAACYP1A2EPHX1CES2CES1 | |
| SCHEMBL16703624 | 0.79 | NAAA (0.36) | NAAACYP1A2EPHX1CES2CES1 | |
| SCHEMBL10959885 | 0.76 | NAAA (0.56) | NAAACES2CES1 | |
| SCHEMBL10962978 | 0.76 | NAAA (0.56) | NAAACES2CES1 | |
| SCHEMBL10960947 | 0.76 | NAAA (0.56) | NAAACES2CES1 | |
| SCHEMBL2126029 | 0.76 | NAAA (0.56) | NAAACES2CES1 | |
| SCHEMBL2126868 | 0.76 | NAAA (0.56) | NAAACES2CES1 | |
| SCHEMBL10960790 | 0.76 | NAAA (0.56) | NAAACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572892-A4 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1572892-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2003033671-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-24 | — | — | WO | disclosed |